


Claims:

1. Use of Compound I of the following formula



or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of uveal melanoma.

2. The use according to claim 1 wherein the uveal melanoma is a metastizing uveal melanoma.
3. The use according to claim 1 wherein the uveal melanoma expresses c-kit.
4. The use according to claim 1 wherein Compound I is in the form of the monomethanesulfonate salt.
5. The use according to claim 4 wherein the monomethanesulfonate salt of Compound I is in the beta crystal form.
6. The use according to claim 1 wherein Compound I is administered at a daily dose corresponding to 100 mg to 1000 mg of Compound I free base.
7. The use according to claim 6 wherein Compound I is administered once daily for a period exceeding 3 months.
8. A method of treating a mammal suffering from uveal melanoma which comprises administering to said mammal in need of such a treatment a dose, effective against said disease, of Compound I or a pharmaceutically acceptable salt thereof.
9. Use of a c-kit inhibitor or a pharmaceutically acceptable salt thereof for the preparation of a medicament for the treatment of uveal melanoma.
10. Use according to claim 9 wherein the uveal melanoma is a metastizing uveal melanoma.